India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals

After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.

Diabetes
PATIENT DATA PERTAINING TO SGLT2 INHIBITORS ARE TO BE EXAMINED IN INDIA

More from Drug Safety

More from Pink Sheet